Polyamyna Preps for Clinical Trials

St. John’s-based disinfectant maker Polyamyna Nanotech has inked a deal with Eastern Health to run clinical trials of its product once it receives Health Canada approval.
Polyamyna, which graduated from the Genesis Evolution program in January, says its disinfectant has been proven by third-party testing to kill antimicrobial-resistant pathogens, sometimes called “superbugs.” It can be used to